RESVITA BIO, INC.

Biotech · Private

Genetically engineered bacteria applied topically to deliver LEKTI protein fragments for treating Netherton syndrome

Grants
$2.5M
4 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Skin probiotics to treat Netherton Syndrome$249,935
Federal grantDepartment of Health and Human Services · Phase I · Skin probiotics to treat atopic dermatitis$249,935
Federal grantDepartment of Health and Human Services · Phase II · Skin probiotics to treat Netherton Syndrome$1,330,533
Federal grantDepartment of Health and Human Services · Phase II · Skin probiotics to treat Netherton Syndrome$703,229
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2325Abiologics——
2326APT THERAPEUTICS, INC.——
2327Landos Biopharma—$60M
2328RESVITA BIO, INC.——
2329CALLENTIS CONSULTING GROUP LLC——
2330Protein Dynamic Solutions, Inc.—$3.4M
2331GlycoEra——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Methods Of Treating Skin Conditions Using Genetically Engineered Microorganismsapplication
  • Methods Of Treating Skin Conditions Using Genetically Engineered Microorganismsapplication
  • Methods Of Treating Skin Conditions Using Genetically Engineered Microorganismsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.